SOFINNOVA-PARTNERS
14.3.2024 11:01:28 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that its portfolio company, Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases has entered into a definitive agreement with AstraZeneca for its acquisition, with an upfront purchase price of $800 million and a potential milestone payment of $250 million.
“We are proud of the remarkable achievements of our team, developing a therapeutic portfolio tackling unmet needs for rare endocrine and related diseases. Last year's Series C financing laid the foundation for the momentum with eneboparatide, propelling us forward to partner with Alexion, AstraZeneca Rare Disease, to bring innovative therapies to patients with rare endocrinology diseases globally. We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
“Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” noted Cédric Moreau, Partner with the Sofinnova Crossover Strategy.
“This marks our second successful exit within the past year, reaffirming the strength of our Crossover Strategy and our longstanding presence in the endocrinology space. Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: “Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency. As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialisation of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this programme, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable our expansion into rare endocrinology.”
Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in Phase 3. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in Phase 1.
Terms of the agreement
Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.
Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314071786/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea Awarded Integrated EPC Contract for Deepwater Development17.3.2026 13:30:00 CET | Press release
Award adds to OneSubsea’s project pipeline and reinforces its standardized system design Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a multi-well, integrated engineering, production, and construction (EPC) contract by China National Offshore Oil Corporation (CNOOC). The contract encompasses 20 wells and covers the delivery of integrated subsea production systems for the deepwater Kaiping 18-1 field development in the South China Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317076557/en/ SLB OneSubsea will deliver standardized subsea production technology that includes dual electric submersible pump (ESP), gas lift and gas injection horizontal trees, manifolds, connectors, and control systems, along with installation and commissioning support. Under the contract, SLB OneSubsea will deliver standardized subsea production technology that includes
HyperLight Introduces 400G-per-lane TFLN PICs on its Chiplet™ Platform for Next-Generation AI Interconnects17.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”), creator of the TFLN Chiplet™ Platform, today announced the availability of 400G-per-lane thin-film lithium niobate (TFLN) photonic integrated circuits (PICs) designed for next-generation AI networking infrastructure. The new PIC family delivers low insertion loss, low drive voltage operation, and exceptional electro-optic bandwidth, enabling energy-efficient and high-performance 400G-per-lane optical links. The transition to 400G-per-lane is a critical step for future AI infrastructure, enabling higher interconnect bandwidth and improved system density. HyperLight’s 400G-per-lane TFLN PICs provide the large electro-optic bandwidth and low-voltage operation required to support these next-generation optical links, where bandwidth, signal integrity, and power efficiency are increasingly challenging for electronic ICs to sustain. HyperLight’s TFLN devices combine high modulation efficiency with extremely low optical loss, enabling transmitter architec
Klarna Smashes 1 Million Merchants Milestone17.3.2026 13:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, has surpassed 1 million merchants globally. Klarna has grown the number of merchants offering its payment methods by 47% in the past year, adding 285,000 merchants in 2025, and more than 115,000 in the final quarter alone. The growth is being driven by Klarna's expanding agreements with the world's leading payment service providers, giving merchants around the world easier access to Klarna at checkout. Leisure, Sport & Hobby is now Klarna's fastest-growing merchant category, up 91% YoY in February 2026, reflecting growing consumer demand for flexible payments in wellness and fitness. David Sykes, Chief Commercial Officer at Klarna: "Home repairs, a new couch, salon appointments, gym memberships - these are facts of life for most people, but the way they pay for them hasn't kept up. Reaching 1 million merchants is a reflection of how deeply embedded Klarna is becoming in everyday money management, and the acceleration acros
Armis Warns Cyberwarfare Threats at Global Tipping Point as AI Accelerates Escalation17.3.2026 13:00:00 CET | Press release
65% of IT decision-makers believe the convergence of AI, quantum, and emerging technologies will drive unprecedented escalation in cyber conflict Half of respondents say cyberwarfare threat is imminent and have had to report an act of cyberwarfare to authorities Armis, the cyber exposure management & security company, is warning that cyberwarfare threats have reached a global pressure-cooker moment. As emerging technologies accelerate cyber operations and geopolitical tensions worsen, attackers are increasingly targeting the infrastructure, information, and systems that underpin global stability. “Geopolitical tensions, AI acceleration, and unresolved security gaps are colliding, bringing the state of cyberwarfare to a boiling point,” said Nadir Izrael, CTO and Co-Founder of Armis. “Cyberwarfare is now a constant condition; attackers are operating at machine speed, while too many organizations are still trying to defend themselves with assumptions and structures built for a very differ
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates17.3.2026 13:00:00 CET | Press release
Fifth edition of Hologic Global Women’s Health Index reveals over half of women worldwide weren’t tested for key conditions in the past yearHologic and Gallup convene experts to discuss closing gaps in screening access Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317786907/en/ Hologic Global Women's Health Index Fifth Edition The data are part of the fifth edition of the Hologic Global Women’s Health Index developed in partnership with Gallup. Based on an annual survey of 145,000 people in 144 countries and territories, the Index tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom